MedTrace Logo

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

NCT07671092 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-16

No results posted yet for this study

Summary

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Conditions

  • Metastatic Urothelial Carcinoma
  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • NSCLC

Interventions

DIAGNOSTIC_TEST

RYZ211/212

Imaging Agent

Sponsors & Collaborators

  • RayzeBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Freddy Escorcia · RayzeBio, Inc.

  • Heying Duan · RayzeBio, Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-07-31
Completion
2027-10-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07671092 on ClinicalTrials.gov